RIGL
RIGEL PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$46.72
+1.63%Oct 19, 2026, 12:05 UTC
Rigel Pharmaceuticals announced that pooled efficacy and safety data from the ARROW and F. Hoffmann-La Roche AG trials of GAVRETO in patients with RET fusion-positive solid tumors will be presented at the ESMO Congress on October 25, 2026.
Source:Oct 2, 2026, 12:05 UTC
Rigel Pharmaceuticals granted inducement equity awards to newly hired employees under its Inducement Plan, approved by its Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).
Source:Aug 5, 2026, 02:05 UTC
Rigel Pharmaceuticals plans to launch its newly licensed breast cancer therapy VEPPANU in mid-August 2026.
Source:Aug 4, 2026, 22:16 UTC
Rigel Pharmaceuticals reported Q2 2026 earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share, and down from $3.28 per share a year ago.
Source:Aug 4, 2026, 14:06 UTC
Arvinas entered into an out-licensing agreement for VEPPANU with Rigel Pharmaceuticals in the first half of 2026.
Source:Jun 17, 2026, 00:00 UTC
Rigel Pharmaceuticals completed the acquisition of exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) from Arvinas entities and Pfizer.